Janus Henderson Group PLC Catalyst Pharmaceuticals, Inc. Transaction History
Janus Henderson Group PLC
- $187 Billion
- Q3 2024
A detailed history of Janus Henderson Group PLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 360,191 shares of CPRX stock, worth $7.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
360,191
Previous 2,175,641
83.44%
Holding current value
$7.9 Million
Previous $33.7 Million
78.75%
% of portfolio
0.0%
Previous 0.02%
Shares
14 transactions
Others Institutions Holding CPRX
# of Institutions
327Shares Held
94.6MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$410 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$176 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$137 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$125 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$66.2 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.25B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...